Keep Factually independent
Whether you agree or disagree with our analysis, these conversations matter for democracy. We don't take money from political groups - even a $5 donation helps us keep it that way.
Who were Neurocept's major shareholders or investors in 2022 versus 2023?
Executive summary
The available materials assembled for this fact-check do not identify Neurocept’s major shareholders or investors for 2022 versus 2023; the documents either reference a different company (Neurogene), are promotional product pages, or are unrelated commentary, so the central claim cannot be verified from the supplied sources. No source in the package contains an explicit, dated roster of Neurocept investors or Schedule 13G/13D filings for the years 2022 and 2023, meaning any definitive statement about changes in major ownership across those years would require consulting primary regulatory filings or company disclosures not present here [1] [2].
1. Why the supplied filings point away from Neurocept and what that means for verification
The document labeled as SEC filings references Neurogene Inc., not Neurocept, and lists various periodic reports and SCHEDULE 13G/A entries that would normally disclose beneficial ownership if they applied to the target company; this suggests a company-name mismatch in the evidence set and undermines direct verification of Neurocept’s ownership from these items. The analysis notes the Neurogene listing but explicitly states it “does not directly mention Neurocept” and that further review of the specific filings would be required to determine ownership [1]. Given the centrality of exact corporate identity for securities disclosures, mixing up Neurogene and Neurocept makes the provided filings insufficient to answer who held major stakes in Neurocept in either year. The absence of Neurocept-specific SEC or corporate records in the package is decisive: you cannot infer Neurocept’s 2022–2023 ownership from filings about a different legal entity.
2. Promotional and topical sources in the package are unreliable for investor data
A supplied page identified as the “Neurocept™ (Official Website)” is a commercial product or supplement site focused on ingredients, benefits and customer service, not on corporate governance or investor listings; company marketing sites often omit ownership details and can be purposefully opaque about investors, which limits their usefulness for shareholder verification [2]. Two other entries discuss the concept of “neuroception” and applications of polyvagal theory in leadership and finance rather than corporate ownership; these are topical or educational pieces and do not provide ownership or investor rosters [3] [4]. Because promotional and topical content can reflect commercial or reputational agendas—either to sell product or to popularize concepts—relying on them in lieu of SEC filings or audited financial statements would be methodologically unsound.
3. The missing primary sources you need: where ownership data normally lives
To determine major shareholders or investors for a private or public company across specific years, the appropriate primary sources are SEC filings (Form 10-K, 10-Q, 8-K and Schedule 13D/G), annual reports, proxy statements, and definitive press releases about financing rounds; institutional investor filings and investor presentations also matter. The analysis notes that Schedule 13G/A filings would typically report beneficial ownership and that reviewing those specific filings is necessary for a definitive answer [1]. Because none of the supplied items contains Neurocept-specific filings, the responsible next step is to locate Neurocept’s SEC filings (for a public company) or company press releases and financing statements (for a private company) covering calendar years 2022 and 2023.
4. Alternative explanations and potential agendas in the provided materials
Two plausible explanations emerge from the evidence set: either the research packet mistakenly substitutes Neurogene documents for Neurocept, or the term “Neurocept” in some items refers to a product or concept rather than the legal entity whose investors you seek. Such conflation can mask the true ownership trail and could be caused by sloppy data collection or purposeful ambiguity on promotional pages [1] [2]. The promotional site carries a commercial agenda; the topical articles aim to educate and may not prioritize corporate transparency; the Neurogene filings, if relevant to a different company, reflect a cataloging rather than targeted disclosure. Each of these agendas explains why investor lists are absent.
5. Practical next steps to produce a verified comparison for 2022 versus 2023
To answer the original question definitively, obtain Neurocept-specific primary documents: search the SEC EDGAR database for Neurocept filings or Schedules 13D/G covering 2021–2024, review company investor relations pages and press releases for funding rounds in 2022 and 2023, and consult state business registries or private placement notices if the company is private. If you suspect a name confusion with Neurogene, retrieve Neurogene’s filings noted in the packet and cross-check corporate identifiers (CIK, legal domicile) to confirm whether any of those filings actually pertain to Neurocept [1]. Only after assembling those primary records can one compile an authoritative list of major shareholders and document any year-over-year changes.